Last reviewed · How we verify
Reduce need for replacement therapy in hemophilia patients following tooth extraction — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Cyklokapron | Tranexamic Acid | Pfizer Inc. | Antifibrinolytic agent | Plasminogen lysine binding sites; fibrin |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer Inc. · 1 drug in Reduce need for replacement therapy in hemophilia patients following tooth extraction
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Reduce need for replacement therapy in hemophilia patients following tooth extraction:
- Reduce need for replacement therapy in hemophilia patients following tooth extraction treatment updates — RSS
- Reduce need for replacement therapy in hemophilia patients following tooth extraction treatment updates — Atom
- Reduce need for replacement therapy in hemophilia patients following tooth extraction treatment updates — JSON
Cite this brief
Drug Landscape (2026). Reduce need for replacement therapy in hemophilia patients following tooth extraction — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/reduce-need-for-replacement-therapy-in-hemophilia-patients-following-tooth-extraction. Accessed 2026-06-10.
Related
- Reduce need for replacement therapy in hemophilia patients following tooth extraction full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing